XM does not provide services to residents of the United States of America.

India's Nifty 50 may open marginally higher; Cipla in focus



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>INDIA STOCKS-India's Nifty 50 may open marginally higher; Cipla in focus</title></head><body>

Nov 14 (Reuters) -India's benchmark Nifty 50 index is set to open marginally higher on Thursday after sinking into correction territory in the previous session, while in-line U.S. inflation data boosted expectations of a Federal Reserve rate cut in December.

The Gift Nifty futures GIFc1 were trading at 23,622 as of 08:18 a.m. IST, indicating that the benchmark Nifty 50 .NSEI will open slightly above Wednesday's close of 23,559.05.

The Nifty and BSE Sensex .BSESN logged the biggest single-day drop in nearly six weeks, losing about 1.3% each, as rising domestic inflation dampened hopes of a rate cut by the Reserve Bank of India (RBI) in the near-term and added to worries over dull corporate earnings and $15 billion foreign outflows in the last 33 sessions.

The Nifty closed 10.34% below the record high it hit on Sept. 27, confirming a technical correction, with the Sensex also flirting with the correction territory.

The broader small- .NIFSMCP100 and mid-caps .NIFMDCP100 also ended their last session more than 10% below the record highs they hit on Sept. 6 and Sept. 24, respectively.

There might be a small bounce after the drop in the last two sessions, but it's unlikely to change the overall trajectory as uncertainty and indecisiveness among traders prevail, said two traders.

Weak China markets dragged broader Asian shares lower on the day as investors remained unimpressed by Beijing's latest stimulus measures to support economy.

Wall Street equities closed slightly higher overnight as the October inflation data showed consumer prices rising in line with expectations, likely keeping the Fed on track for a December rate cut. MKTS/GLOB

The odds of a 25-basis-points cut next month rose to about 83% from 59% a day ago, according to CME FedWatch.

Among individual stocks, drug maker Cipla CIPL.NS could see some pressure after the U.S. drug regulator issued eight observations to the pharma firm's Bengaluru facility.


STOCKS TO WATCH

** Motorcycles maker Eicher Motors EICH.NS posts bigger-than-expected profit in the September-quarter, helped by increased sales of its higher-capacity models such as the "Himalayan".

** Industrial equipments maker Thermax THMX.NS reports a bigger-than-expected second-quarter profit, helped by steady demand.


** Hero MotoCorp HROM.NS, Hindustan Aeronautics HIAE.NS, Grasim Industries GRAS.NS and Glenmark Pharmaceuticals GLEN.NS are among the companies scheduled to report their quarterly results later in the day.



Reporting by Bharath Rajeswaran in Bengaluru; Editing by Sumana Nandy

</body></html>

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.